Qualitative detection of the PD-L1 protein by immunohistochemistry in formalin-fixed, paraffin-embedded non-small cell lung carcinomas (NSCLC) helps in identifying patients suitable for treatment with immune checkpoint inhibitors which are associated with enhanced survival (4). This evidence concerns the gene CD274 and non-small cell lung carcinoma.